Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc
Your view on HOPHF
Overview
What the company does, where it operates, and who runs it.
About Hemogenyx Pharmaceuticals Plc
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Vladislav Sandler
- Headquarters
- 60 Gracechurch Street, London, GB
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Vladislav Sandler
- Headquarters
- 60 Gracechurch Street, London, GB
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases.
It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML), subset of acute lymphoblastic leukaemia, and myelodysplastic syndrome conditioning bone marrow transplants to substitute traditional chemotherapy and/or radiation; HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
The company was founded in 2012 and is headquartered in London, the United Kingdom.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Hemogenyx Pharmaceuticals Plc, and the rating behind it. HOPHF last traded at $2.33; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Hemogenyx Pharmaceuticals Plc. Starting points for Hemogenyx Pharmaceuticals Plc: EPS -$1.62, beta 1.41 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Hemogenyx Pharmaceuticals Plc. Hemogenyx Pharmaceuticals Plc does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Hemogenyx Pharmaceuticals Plc. Trailing twelve-month EPS for Hemogenyx Pharmaceuticals Plc stands at -$1.62. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Hemogenyx Pharmaceuticals Plc. Hemogenyx Pharmaceuticals Plc has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Hemogenyx Pharmaceuticals Plc valued side by side against its closest peers. Hemogenyx Pharmaceuticals Plc is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Hemogenyx Pharmaceuticals Plc, and how their positions are changing. At a $14.9M market value, institutional positions materially move Hemogenyx Pharmaceuticals Plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Hemogenyx Pharmaceuticals Plc executives and directors. Shares of Hemogenyx Pharmaceuticals Plc have traded between $0.04 and $2.33 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Hemogenyx Pharmaceuticals Plc. Hemogenyx Pharmaceuticals Plc is a $14.9M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Hemogenyx Pharmaceuticals Plc. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Hemogenyx Pharmaceuticals Plc. Coverage tracks Hemogenyx Pharmaceuticals Plc within Biotechnology (Healthcare). Press releases and market coverage, newest first.